NextCure (NXTC) 10% Owner LLC Buys $27K of Stock
Key Points
- ADAR1 Capital Management, a 10% owner, increased its stake in NextCure to 728,045 shares after buying 5,626 shares.
- NextCure shares recently traded around $5.71, which is about 14.7% above the $4.98 closing price on the day of the purchase.
- The company, operating in the biotechnology sector, has a market cap of about $26.2 million and is focused on developing cancer treatments.
Since the trade, $NXTC is up 4.8% to date (from the $4.98 close on Oct 23, 2026).
Get NextCure text alerts
We text you when insiders, Congress, analysts or big funds move on $NXTC.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated NextCure, Inc. alert may contain errors. Disclosures
ADAR1 Capital Management, LLC bought 5,626 shares of NextCure, Inc. (NXTC) on October 23, 2026, for about $27,170. This purchase raises its total holdings to 728,045 shares. The information comes from a Form 4 filing with the SEC.
The investment was made at an average price of about $4.83 per share, which is below the recent trading price. After this transaction, ADAR1's ownership in NextCure increased by 0.78%.
NXTC
NextCure, Inc.
ADAR1 Capital Management, LLC vs. the S&P 500
Hypothetical returns from ADAR1 Capital Management, LLC's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in NextCure
Several other institutional investors have shown interest in NextCure. Ikarian Capital, LLC holds 288,303 shares valued at approximately $1.65 million after increasing its stake by 49,997 shares. Adage Capital Partners GP L.L.C. owns 277,202 shares worth around $1.58 million, having added 138,601 shares. Renaissance Technologies, LLC has increased its holdings by 110,668 shares, bringing its total to 171,202 shares valued at about $978,419. Millennium Management LLC also expanded its position, acquiring an additional 44,056 shares for a total of 88,112 shares worth roughly $503,560.
NextCure, Inc. Stock Up 9.8%
NextCure shares closed at $4.98 on October 23, 2026, the same day ADAR1 made its purchase. The stock has been trading recently around $5.71, which is about 14.7% higher than its closing price at the time of the purchase. However, it remains below its 50-day moving average of about $6.15 and its 200-day average of about $7.99, indicating some challenges in price recovery.
Recent Earnings
NextCure has not reported any revenue in its trailing twelve months, and its net margin stands at 0.0%. The company is in the clinical-stage of developing treatments for cancer, focusing on innovative biopharmaceutical solutions.
Insider Buying and Selling at NextCure, Inc.
In June 2026, several insiders bought shares of NextCure. David Kabakoff purchased 3,510 shares, while Stephen Webster, John Houston, and Elaine Jones each bought 2,340 shares. These purchases reflect insider confidence in the company's future prospects.
Analysts Set New Price Targets
The company has a mean price target of $20.00 based on one analyst opinion, suggesting a potential upside from current levels.
About NextCure
NextCure, Inc. is a clinical-stage biopharmaceutical company based in Baltimore, Maryland. It focuses on developing medicines to treat cancer, with its lead product candidate being LNCB74, designed to target and kill tumors. The firm operates within the healthcare sector, specifically in biotechnology, and has a workforce of about 40 employees.
Bottom Line
NextCure continues to attract interest from institutional investors, as seen with ADAR1's recent purchase. Investors should keep an eye on future earnings reports and any developments in the company's product pipeline. The next earnings date has not been announced yet.
Related Filing Alerts
Source: ADAR1 Capital Management, LLC's Form 4 filing on $NXTC (Oct 23, 2026). Written by software, not financial advice. How we make alerts